Tirzepatide (compounded) Reference

Educational, not medical advice reference for Tirzepatide (compounded): GLP-1, Fat Loss; regulatory status, evidence posture, source review, and…

Plain English

What it is
Tirzepatide is a weekly shot (an injection given under the skin) sold under the brand names Mounjaro and Zepbound. It acts like two natural gut hormones, called GIP and GLP-1. A compounded version is a copy mixed by a pharmacy, not the brand-name product that regulators reviewed.
What people use it for
The brand-name versions are approved to help adults with obesity lose weight and keep it off, and to treat a serious sleep-breathing condition (obstructive sleep apnea) in adults with obesity. The same medicine, branded Mounjaro, is also approved for type 2 diabetes. People reach for compounded copies as a stand-in for these same goals.
What the science shows
Large, high-quality human studies show it leads to major weight loss. In one head-to-head trial it beat another popular weight-loss drug, semaglutide, on weight. That strong evidence comes from the brand-name drug, not from compounded copies.
The catch
Compounded vials are not the FDA-reviewed product, so no agency checks their strength, quality, or safety before they reach people, and the FDA has proposed blocking large-scale pharmacy compounding of it. The brand-name drug also carries a boxed warning (the strongest kind of warning) about thyroid tumors seen in animal studies, and stomach side effects like nausea, vomiting, and diarrhea are common.

Reference summary

Tirzepatide is the most-studied GIP plus GLP-1 dual agonist with publicly reported pivotal data. SURMOUNT-1 (Jastreboff 2022 NEJM, PMID 35658024, n=2,539 adults with obesity, 72 weeks) reported mean body-weight reductions of 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg versus 3.1 percent on placebo. SURPASS-2 (Frias 2021 NEJM, PMID 34170647, n=1,879 adults with type 2 diabetes, 40 weeks, open-label head-to-head against semaglutide 1 mg) reported HbA1c reductions of -2.01, -2.24, and -2.30 percentage points at 5, 10, and 15 mg of tirzepatide versus -1.86 with semaglutide; weight differences favored tirzepatide by -1.9, -3.6, and -5.5 kg at the three doses. SURMOUNT-5 (Aronne 2025 NEJM, PMID 40353578, head-to-head against semaglutide 2.4 mg in obesity) showed tirzepatide produced greater weight loss than maximum-dose semaglutide. SURMOUNT-OSA (Malhotra 2024 NEJM, PMID 38912654) ran two parallel Phase 3 trials in obstructive sleep apnea plus obesity (52 weeks): in trial 1 (no positive airway pressure at baseline) the apnea-hypopnea index fell 25.3 events per hour on tirzepatide versus 5.3 on placebo (estimated treatment difference -20.0 events per hour); in trial 2 (on PAP) the AHI fell 29.3 versus 5.5 (treatment difference -23.8). SUMMIT (Packer 2025 NEJM, PMID 39555826, n=731, median 104 weeks) showed tirzepatide reduced the composite of adjudicated cardiovascular death or worsening heart failure events in obesity-driven HFpEF (hazard ratio 0.62, 95 percent CI 0.41 to 0.95, P 0.026) and improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points more than placebo. SYNERGY-NASH (Loomba 2024 NEJM, PMID 38856224, Phase 2 dose-finding, n=190 with biopsy-confirmed MASH and stage F2 or F3 fibrosis, 52 weeks) reported MASH resolution without worsening fibrosis in 44, 56, and 62 percent of the 5, 10, and 15 mg arms versus 10 percent on placebo. Common adverse events across the program are class-typical gastrointestinal events (nausea, diarrhea, vomiting, constipation, decreased appetite), mostly mild to moderate and concentrated during dose escalation.

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
Tirzepatide, Zepbound label reference, Mounjaro active ingredient, LY3298176, GIP / GLP-1 dual receptor agonist
Evidence posture
human
Regulatory status
Tirzepatide is FDA-approved as the GIP plus GLP-1 dual-receptor agonist Mounjaro (NDA 215866, approved May 13, 2022) for type 2 diabetes, and as Zepbound (NDA 217806, approved November 8, 2023) for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity. The Zepbound label was expanded on December 20, 2024 to include treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Both labels carry a boxed warning for risk of thyroid C-cell tumors, contraindications in personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, and warnings for pancreatitis, gallbladder disease, severe gastrointestinal events, acute kidney injury due to volume depletion, hypersensitivity reactions, severe hypoglycemia (especially when combined with insulin or sulfonylureas), diabetic retinopathy in type 2 diabetes, and acute injury related to suicidal thoughts or behavior monitoring. Compounded tirzepatide preparations sold outside FDA-approved manufacturing are not the FDA-approved drug under any approved framework; identity, purity, vial concentration, and syringe-unit accuracy of those preparations cannot be assumed from the trial data. The FDA has explicitly flagged dosing errors and identity issues in the broader compounded GLP-1 space. The FDA tirzepatide shortage was resolved in December 2024; with tirzepatide off the shortage list, large-scale compounding of copies is restricted, and in April 2026 the FDA proposed excluding tirzepatide from the 503B outsourcing-facility bulks list (public comment open through June 29, 2026). Patient-specific 503A compounding remains the narrow lawful pathway.
Content review status
approved label reference

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.